![]() |
|
![]() |
| Does that logic apply to the State - usu plaintiff?
Doesn't seem so since they have seemingly endless capital but have limits in what they can bring to bear. You tell me... |
![]() |
| If by "multi-modal", you mean "it takes several different datatypes as input or output", then yes, it's multi-modal. See Figure 1 in the Tech Report. |
![]() |
| It’s about like referring to a famous person’s red carpet attire as “off the shelf [designer name]”. It downplays the effort that went into it more than anything. |
![]() |
| How hard would it be for a biohacker to use these models to develop novel proteins? Let's say I wanted to take GFP and create another color fluorescent or something. |
![]() |
| The title in HN is inaccurate. Having a 1% higher score on one metric is not beating a previously published model. This is a replicate, which is fine enough. |
![]() |
| > “-150 a new model isn’t released in the next month claiming it is currently the best at something” would let me retire years early.
An optimist and their seed funding are easily parted. |
![]() |
| I'm the author of AutoDock Vina (the most cited docking program, and the "runner-up" in the AlphaFold 3 paper)
Docking software is used to scan millions and billions of drug-like molecules looking for new potential binders. So it needs to be able to generalize, rather than just memorize. But the evaluation approach used here and in the original paper (1) does not test how well the software will perform on novel molecules, because the test set is related to the training set. If you understand the basics of ML and physics, you may be interested in my detailed critique here: https://olegtrott.substack.com/p/are-alphafolds-new-results-... I'm glad that Chai-1 has been released though, as this will probably help people evaluate the method better. (1) It looks like they are a bit different, as this paper allows 40% sequence identity. It's still high. I believe that sequences with 40% identity tend to have the same shapes, especially in the binding site, where it matters. |
For rest of us, this is a privilege that we don't have. We can't deceive, defraud our investors because it has real consequences....but not for people like Matt Schumer, why is that?